February 5, 2023

Volume XIII, Number 36

Error message

  • Warning: Undefined variable $settings in include_once() (line 135 of /var/www/html/docroot/sites/default/settings.php).
  • Warning: Trying to access array offset on value of type null in include_once() (line 135 of /var/www/html/docroot/sites/default/settings.php).
Advertisement

February 03, 2023

Subscribe to Latest Legal News and Analysis

February 02, 2023

Subscribe to Latest Legal News and Analysis
Advertisement

HHS OGC Weighs in On Sub-Regulatory Guidance in Advisory Opinion: What It Might Mean for False Claims Acts Cases After Azar v. Allina Health Services

The U.S. Supreme Court’s 2019 decision in Azar v. Allina Health Services1 effectively curtailed the enforceability of certain Medicare policies established without notice-and-comment rulemaking. As a result, health care fraud cases brought under the False Claims Act (FCA), which are predicated on sub-regulatory guidance, face heightened scrutiny after Allina.2   

In a recent Advisory Opinion, the Health and Human Services Office of the General Counsel (HHS-OGC) provided its interpretation of Allina and how violations of sub-regulatory guidance affect the ability of governmental enforcement agencies and relators to bring and support FCA actions moving forward.3 Specifically, on 3 December 2020, HHS-OGC issued Advisory Opinion 20-05 on Implementing Allina. While HHS-OGC considers the Advisory Opinion nonbinding and it lacks the force of law, the Advisory Opinion provides HHS-OGC’s current views on the implementation of Allina, specifically surrounding the definition and interpretation of a “substantive legal standard.”  Key takeaways are as follows:

  • After Allina, policies that establish or change substantive legal standards related to the scope and award of benefits under the Medicare Act are likely unenforceable as predicates to FCA actions unless promulgated under the formal rulemaking process. Allina has cast doubt on the viability of many health care fraud claims commonly brought under the FCA.

  • The Advisory Opinion offers HHS-OGC’s interpretation of Allina, stating that claims citing to guidance that is closely tied to statutory or regulatory requirements may continue, however, guidance that creates policies or rules not closely tied to statutory or regulatory requirements cannot be the basis for an enforcement action. 

  • Considering Allina, recent court opinions, and the Advisory Opinion, collectively, defendants facing FCA actions based solely on violations of sub-regulatory guidance may have a strong argument that falsity under the FCA cannot be established if the guidance is not tied directly to statutory or regulatory text and was issued without proper notice-and-comment rulemaking. 

  • The impact of Allina on the Government’s and relators’ ability to pursue FCA actions predicated on improperly issued sub-regulatory guidance is unknown but key to that determination will be how narrowly guidance must be tailored to existing statutes or regulatory requirements. 

A review of Allina and the Advisory Opinion are described in further detail below.

THE ALLINA DECISION 

In Allina, the Supreme Court considered whether HHS was required to undertake notice-and-comment rulemaking under the Medicare Act before implementing a change to a Medicare reimbursement formula.4 According to the Supreme Court, while statements of policy may be treated as interpretive rules under the Administrative Procedure Act  and, therefore, do not require notice-and-comment rulemaking, the Medicare Act’s more stringent regulatory framework provides that “‘statements of policy’ can establish or change a ‘substantive legal standard.’”5 Consequently, under the terms of the Medicare Act, any issuance that “establishes or chang[es] a substantive legal standard” governing the scope of Medicare benefits, including the eligibility to provide services and payment for services, must undergo notice-and-comment rulemaking.6 

Key to the Court’s 7–1 decision is its holding that “when the government establishes or changes an avowedly ‘gap’-filling policy, it can’t evade its notice-and-comment obligations under [the Medicare Act] § 1395hh(a)(2)….”7 In practice, Allina means that any policy interpreting a broadly worded statute or regulation related to the scope and award of benefits under the Medicare Act is unenforceable absent this formal rulemaking process.8  

HHS-OGC’S INTERPRETATION OF ALLINA 

Allina did not define the term “substantive legal standard.” However, the Advisory Opinion attempts to set forth HHS-OGC’s current views for determining what may fall under the term’s umbrella. First, HHS-OGC interprets a substantive legal standard as:

any issuance that: (1) defines, in part or in whole, or otherwise announces binding parameters governing, (2) any legal right or obligation relating to the scope of Medicare benefits, payment by Medicare for services, or eligibility of individuals, entities, or organizations to furnish or receive Medicare services or benefits, and (3) sets forth a requirement not otherwise mandated by statute or regulation.9

Second, the Advisory Opinion explains that the critical question under Allina is “whether the violation of the Medicare rule can be shown without the guidance document.”10 A claim citing to guidance that is closely tied to statutory or regulatory requirements may be enforceable, as it does not establish or change a substantive legal standard as prohibited under Allina.11 However, if the guidance creates policies or rules not closely tied to statutory or regulatory text, the guidance is not properly issued under Allina and cannot be the predicate for an enforcement action.   

ALLINA AND THE FCA IN THE COURTS TO DATE

Allina has cast doubt on the viability of many health care fraud claims commonly brought under the FCA. Specifically, in FCA actions, the Government and relators often base allegedly false claims on sub-regulatory guidance that was not subject to notice-and-comment rulemaking. As of December 2020, at least one federal district court applying Allina to an FCA case maintained that dismissal was appropriate because the claims at issue were improperly premised on sub-regulatory guidance.12  In Polansky v. Executive Health Resources, Inc., the district court considered the viability of an FCA action based on a Centers for Medicare & Medicaid Services (CMS) policy, set forth in the 1981 CMS Manual, which classified outpatients as those that spent less than 24 hours in the hospital.13  Applying the holding in Allina, the district court considered whether the 24-hour CMS reimbursement policy was a substantive legal standard within the scope of Section 1395hh(a)(2). Polansky adopted the D.C. Circuit’s opinion that a substantive legal standard is one that “includes a standard that creates, defines, and regulates the rights, duties, and powers of parties.”14 The district court elaborated on this interpretation, stating that “if a policy affects the right to, or amount of reimbursement, it is more likely to be deemed a ‘substantive legal standard.’”15 Accordingly, as the 24-hour policy affected a hospital’s right to payment—setting the standards by which a hospital was entitled to reimbursement rates—the policy was a substantive legal standard that required notice and comment prior to implementation.16 

WHAT TO EXPECT NEXT 

While the Supreme Court has not weighed-in on the meaning of “substantive legal standards,” the Advisory Opinion, with the additional context provided by Polansky, demonstrates the challenge the Government and relators may face in FCA matters moving forward. The Advisory Opinion acknowledges the practical thrust of Allina’s holding: Much of the Medicare guidance previously relied upon by the Government as the basis for claims is unenforceable, absent notice-and-comment rulemaking. Considering AllinaPolansky, and the Advisory Opinion collectively, defendants facing FCA actions premised solely on violations of sub-regulatory guidance not tied directly to statutory or regulatory text may have a strong argument that falsity under the FCA cannot be established because the guidance itself was issued without proper notice-and-comment rulemaking. 

Polansky provides one example of improperly promulgated sub-regulatory guidance establishing or changing “substantive legal standards.” However, how widely Allina will affect, and possibly foreclose, the Government’s and relators’ ability to pursue FCA actions predicated on improperly issued sub-regulatory guidance is presently unknown. Key to that determination will be how narrowly guidance must be tailored to existing statutes or regulatory requirements. This question is left open by Allina and similarly is unaddressed by the Advisory Opinion’s interpretation of “substantive legal standard.”17   

For example, the Advisory Opinion states that HHS-OGC does not believe Medicare administrative contractors are required to promulgate local coverage determinations (LCDs) using notice-and-comment rulemaking. HHS-OGC reasoned that because LCDs are not binding on all levels of HHS during the administrative appeals process, LCDs do not establish or change substantive legal standards. It is unclear whether this specific rationale extends to the use in FCA actions of transmittals and other guidance documents purportedly interpreting LCDs or whether HHS-OGC’s reasoning will withstand the development of post-Allina case law.

K&L Gates’ investigations, enforcement, and white collar practice group and its health care fraud and abuse practice group will continue to monitor the response to the Allina decision and provide periodic updates on developments as the courts and other Government agencies seek to respond to these questions.


1 Azar v. Allina Health Servs., 139 S. Ct. 1804 (2019).
2 See, e.g., Polansky v. Exec. Health Res., Inc., 422 F. Supp. 3d 916, 931–32 (E.D. Pa. 2019).
3 HEALTH & HUM. SERVS. OFF. OF THE GEN. COUNSEL, ADVISORY OPINION 20-05 ON IMPLEMENTING ALLINA 1 (Dec. 3, 2020), https://www.hhs.gov/sites/default/files/allina-ao.pdf [hereinafter Advisory Opinion].
4 Allina, 139 S. Ct. at 1808; see 42 U.S.C. § 1395hh(a)(2).
5 Allina, 139 S. Ct. at 1811 (emphasis in original). 
6 Id. at 1810. 
7 Id. at 1817. 
8 See id.; Advisory Opinion at 1. 
9 Advisory Opinion at 1–2 (citing Select Specialty Hosp.-Denver, Inc. v. Azar, 391 F. Supp. 3d 53 (D.D.C. 2019)). 
10 Advisory Opinion at 2. 
11 Id. 
12 Polansky, 422 F. Supp. 3d at 931–32.
13 Id. at 919.
14 Id. at 934 (quoting Allina Health Servs. v. Price, 863 F.3d 937, 943 (D.C. Cir. 2017)).
15 Id. 
16 Id. at 934–35.
17 See Advisory Opinion at 2.

Copyright 2023 K & L GatesNational Law Review, Volume X, Number 353
Advertisement
Advertisement
Advertisement

About this Author

John Lawrence Healthcare Lawyer K&L Gates Research Triangle Park NC
Partner

Mr. Lawrence primarily counsels healthcare clients in responding to governmental investigations and defending False Claims Act lawsuits. He has represented both individuals and companies in investigations involving the Department of Justice, U.S. Attorneys' Offices, and other federal and state agencies. His background also includes significant experience handling complex civil litigation inside and outside of healthcare. In addition to his litigation practice, Mr. Lawrence advises clients on healthcare regulatory matters, including those involving the Stark Law and Anti-Kickback Statute....

919-466-1112
Partner

David Rybicki is a partner in the firm’s Washington, D.C. office. He is a member of the investigations, enforcement, and white collar practice group.

Mr. Rybicki recently served in the Criminal Division of the United States Department of Justice in Washington, D.C., as Acting Principal Deputy Assistant Attorney General (2017) and Deputy Assistant Attorney General (2017-2020), the second- and third-highest ranking positions in the division. In these roles, Mr. Rybicki supervised some of the nation’s most significant investigations and prosecutions involving white collar crime, money...

202.778.9370
Joshua I. Skora Healthcare & FDA Attorney K&L Gates Law Firm Dallas
Partner

Josh Skora is a partner in the firm’s Dallas office, where he is a member of the health care & FDA practice group. His national practice focuses on representation of public and closely-held health care companies, such as durable medical equipment suppliers and manufacturers, pharmacies, home health and hospice agencies, home infusion providers, ambulatory surgical centers, laboratories, diagnostic testing facilities, telemedicine providers, behavioral health and substance abuse providers, skilled nursing facilities, long term care facilities, and other ancillary...

214.939.6235
Hayley Trahan-Liptak Litigation Attorney K&L Gates Boston, MA
Associate

Hayley Trahan-Liptak is an associate in the litigation department of the firm’s Boston office. She focuses her practice on general civil and commercial litigation matters. Ms. Trahan-Liptak has experience in financial service litigation, class action defense, appellate advocacy, and general business litigation cases. She also has experience in the firm’s corporate department, assisting with mergers and acquisitions, stock financings, IPOs, and commercial contracts.

Primary Practice

  • Investigations, Enforcement and White Collar

Secondary Practices...

617.951.9148
Advertisement
Advertisement
Advertisement